Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.

Abstract: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.

Abstract: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.

Abstract: The present invention is a composition, preferably a cleanser, comprising sulfur, sodium sulfacetamide and at least one emulsifier with a low HLB number. These compositions are stable and may include moisturizers and humectants. Use of these compositions include treatments for acne rosacea, acne vulgaris and other skin disorders.

Abstract: The present invention is a composition, preferably a cleanser, comprising sulfur, sodium sulfacetamide and at least one emulsifier with a low HLB number. These compositions are stable and may include moisturizers and humectants. Use of these compositions include treatments for acne rosacea, acne vulgaris and other skin disorders.

Abstract: A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a drug dissolved or dispersed in an aqueous medium. The aqueous medium consists essentially of water, about 3% to about 10% w/v polyvinylpyrrolidone, about 60% to about 75% w/v of C3-C6 polyol that includes more than 55% w/v of a non-reducing disaccharide, trisaccharide or tetrasaccharide such as sucrose, optionally about 0.01% to about 0.5% w/v of a glycyrrhetic acid, glycyrrhizinate derivative or salt thereof, and one or more flavorants, and preferably includes one or more preservatives. The liquid composition is room temperature stable, and may have a pleasant taste.

Abstract: The present invention is a composition, preferably a cleanser, comprising sulfur, sodium sulfacetamide and at least one emulsifier with a low HLB number. These compositions are stable and may include moisturizers and humectants. Use of these compositions include treatments for acne rosacea, acne vulgaris and other skin disorders.

Abstract: The present invention relates to a composition comprising two or more anti-irritants, each having at least about 7.2% oxygen content. In a separate embodiment, the composition may be defined to include a skin conditioning agent, a skin protectant agent, and an anti-irritant agent, each having an oxygen content of at least about 7.2%. The invention further comprises methods of treating and preventing skin conditions by applying the composition to the skin, and then optionally washing the skin.

Abstract: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.

Abstract: A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of prednisolone sodium phosphate (PSP) dissolved or dispersed in an aqueous medium that is free of ethanol. The aqueous medium consists essentially of water, about 3 to about 10 weight percent polyvinylpyrrolidone, about 60 to about 75 weight percent of a C3-C6 polyol that includes more than 55 weight percent non-reducing disaccharide or trisaccharide such as sucrose, about 0.01 to about 0.5 weight percent ammonium glycyrrhizinate and one or more flavorants, and preferably includes one or more preservatives. The liquid composition is transparent and has a pleasant taste.

Abstract: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.

Abstract: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.

Abstract: The invention provides methods and means for enhancing the epidermal, transdermal and dermal permeation of a topically applied pharmacologically active agent (e.g., a drug or medicament) which has a low rate of skin penetration in the absence of a permeation enhancer and which is unstable and degrades during long-term storage with particular permeation enhancers. Also provided by the invention are methods and means to increase the skin penetration of a pharmacologically active agent which has a normally low rate of skin permeation and causes the instability and degradation of a permeation enhancer with which it is combined over a long period of time. Provided by the invention are at least one first composition containing a drug, a pharmaceutically acceptable salt, chemical derivative or formulation thereof, in a dermatologically acceptable vehicle, and at least one second composition containing a permeation enhancer in an acceptable vehicle.

Abstract: A method and system is described for the noninvasive administration of a therapeutic concentration of a deoxyspergualin compound to a patient comprising iontophoretically passing the deoxyspergualin compound through an area of the skin of the patient at a flux effective to provide the therapeutic concentration.